FDA 483 - Gopaldas Visram & Co., Ltd. - January 24, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Gopaldas Visram & Co., Ltd. in Navi Mumbai, India, a drug manufacturer, revealed significant deficiencies across multiple areas. The firm failed to adequately test raw material components before use and lacked proper controls over electronic records, leading to data integrity concerns. Additionally, the quality control unit did not fully adhere to its procedures, and the company inappropriately used "planned deviations" to bypass protocols, indicating serious lapses in quality management and record-keeping practices.
ID · 87b2355a-4d6d-4569-8611-340c1484e10a